Literature DB >> 28350898

Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group.

Claudia Manca1, Carol Hill2, Andrea M Hujer3,4, Robin Patel5,6, Scott R Evans7, Robert A Bonomo3,4, Barry N Kreiswirth1.   

Abstract

The Antibacterial Resistance Leadership Group (ARLG) Laboratory Center (LC) leads the evaluation, development, and implementation of laboratory-based research by providing scientific leadership and supporting standard/specialized laboratory services. The LC has developed a physical biorepository and a virtual biorepository. The physical biorepository contains bacterial isolates from ARLG-funded studies located in a centralized laboratory and they are available to ARLG investigators. The Web-based virtual biorepository strain catalogue includes well-characterized gram-positive and gram-negative bacterial strains published by ARLG investigators. The LC, in collaboration with the ARLG Leadership and Operations Center, developed procedures for review and approval of strain requests, guidance during the selection process, and for shipping strains from the distributing laboratories to the requesting investigators. ARLG strains and scientific and/or technical guidance have been provided to basic research laboratories and diagnostic companies for research and development, facilitating collaboration between diagnostic companies and the ARLG Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND) initiative for evaluation of multiple diagnostic devices from a single patient sampling event. In addition, the LC has completed several laboratory-based studies designed to help evaluate new rapid molecular diagnostics by developing, testing, and applying a MASTERMIND approach using purified bacterial strains. In collaboration with the ARLG's Statistical and Data Management Center (SDMC), the LC has developed novel analytical strategies that integrate microbiologic and genetic data for improved and accurate identification of antimicrobial resistance. These novel approaches will aid in the design of future ARLG studies and help correlate pathogenic markers with clinical outcomes. The LC's accomplishments are the result of a successful collaboration with the ARLG's Leadership and Operations Center, Diagnostics and Devices Committee, and SDMC. This interactive approach has been pivotal for the success of LC projects.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antibacterial resistance; bacterial strains.; biorepository; diagnostics and devices; drug testing

Mesh:

Substances:

Year:  2017        PMID: 28350898      PMCID: PMC5848373          DOI: 10.1093/cid/ciw826

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

Review 1.  Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group.

Authors:  Ephraim L Tsalik; Elizabeth Petzold; Barry N Kreiswirth; Robert A Bonomo; Ritu Banerjee; Ebbing Lautenbach; Scott R Evans; Kimberly E Hanson; Jeffrey D Klausner; Robin Patel
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

2.  MASTERMIND: Bringing Microbial Diagnostics to the Clinic.

Authors:  Robin Patel; Ephraim L Tsalik; Elizabeth Petzold; Vance G Fowler; Jeffrey D Klausner; Scott Evans
Journal:  Clin Infect Dis       Date:  2016-12-07       Impact factor: 9.079

Review 3.  Antibacterial resistance leadership group: open for business.

Authors:  Henry F Chambers; John G Bartlett; Robert A Bonomo; Christine Chiou; Sara E Cosgrove; Heather R Cross; Robert S Daum; Michele Downing; Scott R Evans; Jane Knisely; Barry N Kreiswirth; Ebbing Lautenbach; Brenda S Mickley; Robin Patel; Melinda M Pettigrew; Keith A Rodvold; Brad Spellberg; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2014-03-06       Impact factor: 9.079

4.  Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II.

Authors:  Scott R Evans; Andrea M Hujer; Hongyu Jiang; Kristine M Hujer; Thomas Hall; Christine Marzan; Michael R Jacobs; Rangarajan Sampath; David J Ecker; Claudia Manca; Kalyan Chavda; Pan Zhang; Helen Fernandez; Liang Chen; Jose R Mediavilla; Carol B Hill; Federico Perez; Angela M Caliendo; Vance G Fowler; Henry F Chambers; Barry N Kreiswirth; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2015-09-25       Impact factor: 9.079

Review 5.  Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.

Authors:  Sarah B Doernberg; Thomas P Lodise; Joshua T Thaden; Jose M Munita; Sara E Cosgrove; Cesar A Arias; Helen W Boucher; G Ralph Corey; Franklin D Lowy; Barbara Murray; Loren G Miller; Thomas L Holland
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

6.  Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group.

Authors:  Jacqueline Huvane; Lauren Komarow; Carol Hill; Thuy Tien T Tran; Carol Pereira; Susan L Rosenkranz; Matt Finnemeyer; Michelle Earley; Hongyu Jeanne Jiang; Rui Wang; Judith Lok; Scott R Evans
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

  6 in total
  8 in total

Review 1.  Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group.

Authors:  Ephraim L Tsalik; Elizabeth Petzold; Barry N Kreiswirth; Robert A Bonomo; Ritu Banerjee; Ebbing Lautenbach; Scott R Evans; Kimberly E Hanson; Jeffrey D Klausner; Robin Patel
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

2.  The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.

Authors:  Henry F Chip Chambers; Heather R Cross; Scott R Evans; Barry N Kreiswirth; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

Review 3.  Transforming Concepts Into Clinical Trials and Creating a Multisite Network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group.

Authors:  Heather R Cross; Anthony Harris; Rebekka M Arias; Henry F Chip Chambers; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

Review 4.  Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.

Authors:  Yohei Doi; Robert A Bonomo; David C Hooper; Keith S Kaye; James R Johnson; Cornelius J Clancy; Joshua T Thaden; Martin E Stryjewski; David van Duin
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

5.  Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group.

Authors:  Jacqueline Huvane; Lauren Komarow; Carol Hill; Thuy Tien T Tran; Carol Pereira; Susan L Rosenkranz; Matt Finnemeyer; Michelle Earley; Hongyu Jeanne Jiang; Rui Wang; Judith Lok; Scott R Evans
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

6.  Reporting of master protocols towards a standardized approach: A systematic review.

Authors:  Ellie G Siden; Jay Jh Park; Michael J Zoratti; Louis Dron; Ofir Harari; Kristian Thorlund; Edward J Mills
Journal:  Contemp Clin Trials Commun       Date:  2019-07-04

7.  Control of Infectious Diseases in the Era of European Clinical Microbiology Laboratory Consolidation: New Challenges and Opportunities for the Patient and for Public Health Surveillance.

Authors:  Olivier Vandenberg; Zisis Kozlakidis; Jacques Schrenzel; Marc Jean Struelens; Judith Breuer
Journal:  Front Med (Lausanne)       Date:  2018-02-02

8.  Screening of biomarkers of drug resistance or virulence in ESCAPE pathogens by MALDI-TOF mass spectrometry.

Authors:  Samantha Flores-Treviño; Elvira Garza-González; Soraya Mendoza-Olazarán; Rayo Morfín-Otero; Adrián Camacho-Ortiz; Eduardo Rodríguez-Noriega; Adrián Martínez-Meléndez; Paola Bocanegra-Ibarias
Journal:  Sci Rep       Date:  2019-12-12       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.